Influence of body mass on predicted values of static hyperinflation in COPD by Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jörres RA

Get full text

COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany by Vogelmeier CF, Diesing J, Kossack N, Pignot M, Friedrich FW

Get full text

Differences in the Measurement of Functional Residual Capacity Between Body Plethysmographs of Two Manufacturers by Alter P, Orszag J, Wouters EF, Vogelmeier CF, Jörres RA

Get full text

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population by Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K

Get full text

Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data by Stöber A, Lutter JI, Schwarzkopf L, Kirsch F, Schramm A, Vogelmeier CF, Leidl R

Get full text

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study by Buhl R, Criée C, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H

Get full text

Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis by Buhl R, Wilke T, Picker N, Schmidt O, Hechtner M, Kondla A, Maywald U, Vogelmeier CF

Get full text

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol by Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner CM, Kondla A, Vogelmeier CF

Get full text

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD by Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R

Get full text

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort by Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fähndrich S, Jörres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H

Get full text

The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD/Emphysema, Asthma and Bronchiectasis by Veith M, Tüffers J, Peychev E, Klemmer A, Kotke V, Janciauskiene S, Wilhelm S, Bals R, Koczulla AR, Vogelmeier CF, Greulich T

Get full text

The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort by Wacker ME, Kitzing K, Jörres RA, Leidl R, Schulz H, Karrasch S, Karch A, Koch A, Vogelmeier CF, Holle R

Get full text

Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort by Alter P, Mayerhofer BA, Kahnert K, Watz H, Waschki B, Andreas S, Biertz F, Bals R, Vogelmeier CF, Jörres RA

Get full text

Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology by Veith M, Klemmer A, Anton I, El Hamss R, Rapun N, Janciauskiene S, Kotke V, Herr C, Bals R, Vogelmeier CF, Greulich T

Get full text

Personalized medicine for patients with COPD: where are we? by Franssen FME, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, Maxheim M, Roessler FK, Spruit MA, Vogelmeier CF, Wouters EFM, Schmeck B

Get full text

Basic Determinants of Disease Knowledge in COPD Patients: Results from COSYCONET by Fischer C, Jörres RA, Alter P, Trudzinski FC, Yildirim, Bals R, Vogelmeier CF, Kauffmann-Guerrero D, Behr J, Watz H, Holle R, Kahnert K

Get full text

Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET by Kahnert K, Jörres RA, Lucke T, Trudzinski FC, Mertsch P, Bickert C, Ficker JH, Behr J, Bals R, Watz H, Welte T, Vogelmeier CF, Alter P

Get full text

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study by Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA

Get full text

Characteristics of Current Smokers versus Former Smokers with COPD and Their Associations with Smoking Cessation Within 4.5 Years: Results from COSYCONET by Alter P, Stoleriu C, Kahnert K, Henke MO, Bals R, Trudzinski FC, Watz H, Speicher T, Söhler S, Welte T, Rabe KF, Wouters EFM, Vogelmeier CF, Jörres RA

Get full text

Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences by Lutter JI, Jörres RA, Trudzinski FC, Alter P, Kellerer C, Watz H, Welte T, Bals R, Kauffmann-Guerrero D, Behr J, Holle R, Vogelmeier CF, Kahnert K

Get full text